Articles related to FATIGUE/TIREDNESS

In an adaptive randomized trial of adults with long COVID, fluvoxamine modestly reduced fatigue and improved quality-of-life scores through 90 days, while metformin findings remained inconclusive after dose modification and early termination.

Among 29 CPAP-adherent men with severe obstructive sleep apnea, residual objective sleepiness was associated with white-matter diffusion differences, although the cross-sectional findings do not establish causality or support routine imaging.

In a specialty-clinic cohort of 2,329 adults with Neuro-PASC, females reported more neurologic symptoms, greater fatigue, and, among nonhospitalized patients, poorer attention than males approximately 16 months after symptom onset.

Fluvoxamine reduced fatigue and improved quality-of-life measures in adults with long COVID in a randomized placebo-controlled trial. The findings provide evidence for a potential therapy, although further research is needed to define optimal patient selection and treatment strategies.

A network meta-analysis of 15 randomized trials found that no pharmacologic treatment outperformed placebo for MS-related fatigue severity, though amantadine and fampridine showed statistically significant and potentially clinically meaningful improvements in fatigue-related daily functioning.

Up to 45% of people in the US experience fatigue, making medication-induced drowsiness a significant clinical consideration when prescribing commonly used drug classes.